These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 23139824)
1. Completion of treatment for latent tuberculosis infection with monthly drug dispensation directly through the tuberculosis clinic. Dobler CC; Marks GB PLoS One; 2012; 7(11):e48900. PubMed ID: 23139824 [TBL] [Abstract][Full Text] [Related]
2. Completion rate of latent tuberculosis infection treatment in patients aged 65 years and older. Noh CS; Kim HI; Choi H; Kim Y; Kim CH; Choi JH; Hyun IG; Baek MS Respir Med; 2019 Oct; 157():52-58. PubMed ID: 31522030 [TBL] [Abstract][Full Text] [Related]
3. House calls by community health workers and public health nurses to improve adherence to isoniazid monotherapy for latent tuberculosis infection: a retrospective study. Chang AH; Polesky A; Bhatia G BMC Public Health; 2013 Sep; 13():894. PubMed ID: 24073620 [TBL] [Abstract][Full Text] [Related]
4. Cost of nurse-managed latent tuberculous infection treatment among hard-to-reach immigrants in Israel. Bishara H; Ore L; Vinitsky O; Bshara H; Armaly N; Weiler-Ravell D Int J Tuberc Lung Dis; 2015 Jul; 19(7):799-804. PubMed ID: 26056104 [TBL] [Abstract][Full Text] [Related]
5. Enhancement of treatment completion for latent tuberculosis infection with 4 months of rifampin. Lardizabal A; Passannante M; Kojakali F; Hayden C; Reichman LB Chest; 2006 Dec; 130(6):1712-7. PubMed ID: 17166986 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of 3 Months of Once-Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection. Walker RE; Bass S; Srinivas P; Miranda C; Johnson L; Pallotta AM Ann Pharmacother; 2020 May; 54(5):457-463. PubMed ID: 31729245 [No Abstract] [Full Text] [Related]
7. Adherence to nine-month isoniazid for latent tuberculosis infection in healthcare workers: a prospective study in a tertiary hospital. Chung SJ; Lee H; Koo GW; Min JH; Yeo Y; Park DW; Park TS; Moon JY; Kim SH; Kim TH; Sohn JW; Yoon HJ Sci Rep; 2020 Apr; 10(1):6462. PubMed ID: 32296096 [TBL] [Abstract][Full Text] [Related]
8. Interferon gamma release assay tests are associated with persistence and completion of latent tuberculosis infection treatment in the United States: Evidence from commercial insurance data. Stockbridge EL; Loethen AD; Annan E; Miller TL PLoS One; 2020; 15(12):e0243102. PubMed ID: 33270737 [TBL] [Abstract][Full Text] [Related]
10. Using Video Technology to Increase Treatment Completion for Patients With Latent Tuberculosis Infection on 3-Month Isoniazid and Rifapentine: An Implementation Study. Lam CK; McGinnis Pilote K; Haque A; Burzynski J; Chuck C; Macaraig M J Med Internet Res; 2018 Nov; 20(11):e287. PubMed ID: 30459146 [TBL] [Abstract][Full Text] [Related]
11. A Step toward Tuberculosis Elimination in a Low-Incidence Country: Successful Diagnosis and Treatment of Latent Tuberculosis Infection in a Refugee Clinic. Rennert-May E; Hansen E; Zadeh T; Krinke V; Houston S; Cooper R Can Respir J; 2016; 2016():7980869. PubMed ID: 27445565 [TBL] [Abstract][Full Text] [Related]
12. Treatment completion for latent tuberculosis infection in Norway: a prospective cohort study. Schein YL; Madebo T; Andersen HE; Arnesen TM; Dyrhol-Riise AM; Tveiten H; White RA; Winje BA BMC Infect Dis; 2018 Nov; 18(1):587. PubMed ID: 30453946 [TBL] [Abstract][Full Text] [Related]
13. Use of Rifapentine and Isoniazid Directly Observed Therapy for the Treatment of Latent Tuberculosis Infection in a Military Clinic. Jinbo J; Lustik M; West GF; Kloetzel M Mil Med; 2017 Sep; 182(9):e2024-e2029. PubMed ID: 28885972 [TBL] [Abstract][Full Text] [Related]
14. Seven-year retrospective study understanding the latent TB infection treatment cascade of care among adults in a low incidence country. Sullivan K; Pease C; Zwerling A; Mallick R; Van Dyk D; Mulpuru S; Allen C; Alsdurf H; Alvarez GG BMC Public Health; 2021 May; 21(1):964. PubMed ID: 34020616 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of isoniazid salvage therapy for latent tuberculosis infection in patients with immune-mediated inflammatory disorders - A retrospective cohort study in Taiwan. Huang SF; Chen MH; Wang FD; Tsai CY; Fung CP; Su WJ J Microbiol Immunol Infect; 2018 Dec; 51(6):784-793. PubMed ID: 28739436 [TBL] [Abstract][Full Text] [Related]
16. Impacts of 12-dose regimen for latent tuberculosis infection: Treatment completion rate and cost-effectiveness in Taiwan. Huang YW; Yang SF; Yeh YP; Tsao TC; Tsao SM Medicine (Baltimore); 2016 Aug; 95(34):e4126. PubMed ID: 27559940 [TBL] [Abstract][Full Text] [Related]
17. Evaluating the role of primary care physicians in the treatment of latent tuberculosis: a population study. Rubinowicz A; Bartlett G; MacGibbon B; Greenaway C; Ronald L; Munoz M; Menzies D Int J Tuberc Lung Dis; 2014 Dec; 18(12):1449-54. PubMed ID: 25517810 [TBL] [Abstract][Full Text] [Related]
18. Current Status of Latent Tuberculosis Infection Treatment Among Pediatric Patients in Korea: Prescription and Treatment Completion. Kim Y; Bae KS; Choi UY; Han SB; Kim JH J Korean Med Sci; 2024 Feb; 39(7):e64. PubMed ID: 38412611 [TBL] [Abstract][Full Text] [Related]
19. Diagnosis and treatment of latent tuberculosis infection in patients undergoing treatment with immunobiologic agents: a four-year experience in an endemic area. Lopes DMA; Pinheiro VGF; Monteiro HSA J Bras Pneumol; 2019; 45(6):e20180225. PubMed ID: 31618298 [TBL] [Abstract][Full Text] [Related]
20. A prospective cohort study of outcomes for isoniazid prevention therapy: a nested study from a national QI collaborative in Uganda. Sensalire S; Karungi Karamagi Nkolo E; Nabwire J; Lawino A; Kiragga D; Muhire M; Kadama H; Katureebe C; Namuwenge P; Musinguzi J; Calnan J; Seyoum D AIDS Res Ther; 2020 May; 17(1):28. PubMed ID: 32460788 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]